Myelodysplastic syndromes - Clinicopathologic features, pathobiology, and molecular pathogenesis

被引:0
|
作者
Nishino, HT [1 ]
Chang, CC [1 ]
机构
[1] Methodist Hosp, Dept Pathol, Houston, TX 77030 USA
关键词
D O I
暂无
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Context-Myelodysplastic syndromes (MDSs) are clonal stem cell diseases characterized by ineffective hematopoiesis, multilineage dysplasia, and peripheral cytopenias with normocellular or hypercellular marrow. They represent a heterogeneous group of disorders with a varied spectrum of clinical, morphologic, biologic, and genetic characteristics. This heterogeneity in disease characterization has led to evolving classification systems, developing prognostic models, and continuing research efforts to elucidate its pathobiology and pathogenesis. Objective-To summarize updated information and provide a general overview of the clinicopathologic features, pathobiology, and cytogenetic and molecular pathogenesis of MDSs. Data Sources-Relevant articles indexed in PubMed (National Library of Medicine) between 1982 and 2005 and reference medical texts. Conclusions-Although MDSs remain a relatively poorly defined disease entity, recent advancements in cytogenetic and molecular studies have significantly contributed to our present knowledge of MDSs. Novel strategies for studying the pathogenesis and evolution of MDSs continue to shape our understanding of this disease and guide our approaches to diagnosis and treatment.
引用
收藏
页码:1299 / 1310
页数:12
相关论文
共 50 条
  • [41] Cytogenetic features in myelodysplastic syndromes
    Haase, Detlef
    ANNALS OF HEMATOLOGY, 2008, 87 (07) : 515 - 526
  • [42] Recent advances in myelodysplastic syndromes: Molecular pathogenesis and its implications for targeted therapies
    Harada, Hironori
    Harada, Yuka
    CANCER SCIENCE, 2015, 106 (04) : 329 - 336
  • [43] Molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes
    黄慧君
    China Medical Abstracts(Internal Medicine), 2020, 37 (04) : 233 - 233
  • [44] MOLECULAR FEATURES A PROGNOSTIC VALUE OF RAS MUTATIONS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
    Huang, H.
    Li, B.
    Qin, T.
    Xu, Z.
    Hu, N.
    Pan, L.
    Qu, S.
    Liu, D.
    Zhang, Y.
    Xiao, Z.
    LEUKEMIA RESEARCH, 2021, 108 : S21 - S21
  • [45] The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features
    Greenberg, Peter L.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (07): : 877 - 885
  • [46] Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints
    Hidalgo-Lopez, Juliana E.
    Kanagal-Shamanna, Rashmi
    Quesada, Andres E.
    Thakral, Beenu
    Hu, Zhihong
    Mitsuhashi, Takayuki
    Yabe, Mariko
    Garcia-Manero, Guillermo
    Bueso-Ramos, Carlos E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S16 - S25
  • [47] Primary myelodysplastic syndromes: A clinicopathologic and prognostic assessment.
    Sadighi, S
    Monadizadeh, D
    BLOOD, 2003, 102 (11) : 330B - 330B
  • [48] Pathogenesis, classification, and treatment of myelodysplastic syndromes (MDS)
    Valent, P
    Wimazal, F
    Schwarzinger, I
    Sperr, WR
    Geissler, K
    WIENER KLINISCHE WOCHENSCHRIFT, 2003, 115 (13-14) : 515 - 536
  • [49] Myelodysplastic syndromes: the role of the immune system in pathogenesis
    Warlick, Erica D.
    Miller, Jeffrey S.
    LEUKEMIA & LYMPHOMA, 2011, 52 (11) : 2045 - 2049
  • [50] Pathogenesis, biology, and management of myelodysplastic syndromes in children
    Haas, OA
    Gadner, H
    SEMINARS IN HEMATOLOGY, 1996, 33 (03) : 225 - 235